Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fazirsiran - Arrowhead Pharmaceuticals/Takeda Pharmaceuticals USA

Next Previous
Drug Profile

Fazirsiran - Arrowhead Pharmaceuticals/Takeda Pharmaceuticals USA

Alternative Names: ADS-001; ARO-AAT; Fazirsiran sodium - Arrowhead Pharmaceuticals/Takeda Pharmaceuticals USA; TAK-999

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Developer Arrowhead Pharmaceuticals; Takeda
  • Class Anti-inflammatories; Hepatoprotectants; Small interfering RNA
  • Mechanism of Action Alpha 1-antitrypsin expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alpha 1-antitrypsin deficiency

Most Recent Events

  • 01 Mar 2024 Phase-III clinical trials in Alpha 1-antitrypsin deficiency in USA (SC) (NCT06165341)
  • 14 Dec 2023 Takeda plans a phase III trial for Alpha 1-antitrypsin deficiency (In adults, In the elderly) in unknown location (SC, Injection) (NCT06165341)
  • 05 Oct 2023 Phase-I clinical trials in Alpha 1-antitrypsin deficiency (In volunteers) in Hungary (SC) (NCT05891158)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top